为肝细胞癌武装 GPC3 CAR T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
英文原题:Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors.
由于缺乏体内模型,我们对人肝细胞癌(HCC)发生与进展的认识一直受到限制。
由于缺乏体内模型,我们对人肝细胞癌(HCC)发生和进展的认识受到限制。研究者在Fah基因敲除的免疫缺陷小鼠中,对10种癌基因和基因突变进行筛选;这些小鼠以原代人肝细胞(PHH)重建有功能的人肝脏。研究发现,MYC、TP53 R249S和KRAS G12D在诱导型HCC(iHCC)样本中高表达。单独过表达MYC和TP53 R249S即可在原位将PHH转化为iHCC,而加入KRAS G12D可显著提高致瘤效率。iHCC可重现临床HCC样本的组织学结构和基因表达特征,并能在连续移植后形成HCC。iHCC与PHH的转录组分析显示,MUC1和FAP在iHCC中表达,在正常肝脏中则不表达。靶向这两种表面标志物的嵌合抗原受体(CAR)T细胞可高效裂解iHCC细胞。iHCC模型的特性为HCC多项临床表现提供了生物学依据,也可用于研究HCC起始过程,并寻找诊断生物标志物和细胞免疫治疗靶点。
Our understanding of human hepatocellular carcinoma (HCC) development and progression has been hampered by the lack of in vivo models. We performed a genetic screen of 10 oncogenes and genetic mutations in Fah-ablated immunodeficient mice in which primary human hepatocytes (PHHs) are used to reconstitute a functional human liver. We identified that MYC, TP53 R249S , and KRAS G12D are highly expressed in induced HCC (iHCC) samples. The overexpression of MYC and TP53 R249S transform PHHs into iHCC in situ, though the addition of KRAS G12D significantly increases the tumorigenic efficiency. iHCC, which recapitulate the histological architecture and gene expression characteristics of clinical HCC samples, reconstituted HCC after serial transplantations. Transcriptomic analysis of iHCC and PHHs showed that MUC1 and FAP are expressed in iHCC but not in normal livers. Chimeric antigen receptor (CAR) T cells against these two surface markers efficiently lyse iHCC cells. The properties of iHCC model provide a biological basis for several clinical hallmarks of HCC, and iHCC may serve as a model to study HCC initiation and to identify diagnostic biomarkers and targets for cellular immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。